Compare Cytokinetics Inc (CYTK) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Invesco S&P 500 Low Volatility ETF trades at $72.14 (market cap $6.94B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Cytokinetics Inc is more actively traded (2,594,626 versus 1,663,703). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| CYTK | SPLV | |
|---|---|---|
Market Cap | $8.62B | $6.94B |
Volume | 2,594,626 | 1,663,703 |
Sector | Health | — |
52-Week High | $87.26 | $77.97 |
52-Week Low | $54.76 | $70.30 |
Typical Hold Time | 19 Days | 123 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.91, up 2.93% with bearish technical signals despite strong analyst support. The company shows promising drug development with positive Phase 3 results for aficamten in HCM treatment, though fundamentals remain challenged with a P/S ratio of 114 and negative profit margins. Recent executive stock sales and high cash burn from operations highlight ongoing financial pressures despite growing revenue potential from new drug launches.
The outlook balances significant upside potential from analyst price targets averaging $112.60 against substantial execution risks. While clinical successes position CYTK for growth in cardiovascular treatments, persistent losses and high valuation metrics require careful risk assessment. The stock offers speculative growth opportunity but demands close monitoring of commercialization progress and path to profitability.
SPLV, the Invesco S&P 500 Low Volatility ETF, trades at $72.14 with a 1.29% daily gain, though technical indicators show a bearish trend with moving averages signaling caution. The ETF's sector allocation to Utilities, Real Estate, and Financials has contributed to underperformance relative to the broader S&P 500, with a 5% return versus 17% for the index. Recent dividend distributions of $0.14 per share provide income support amid market volatility.
The outlook remains neutral with valuation concerns at a 19.5x P/E ratio creating headwinds, while geopolitical tensions and sector-specific risks pose challenges. Opportunities exist for investors seeking stability during market uncertainty, though growth potential appears limited compared to broader market ETFs. Key risks include continued sector underperformance and macroeconomic pressures on defensive holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
